ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

VIS171

A development code.

Its studies are mostly in Lupus Erythematosus, Systemic · Autoimmune Diseases, led by Otsuka.

Furthest: phase 1, since Jun 3, 20222 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka21 open or runningphase 1since Jun 3, 2022Jun 3, 2022none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 3, 2022First study: phase 1 study in Autoimmune DiseasesFirst studyNCT05418101 · 61 enrolled · Bulgaria, Germany, Moldova and more
  2. Jan 23, 2025Phase 1 study in Lupus Erythematosus, SystemicNCT06799520 · 30 enrolled · Bulgaria, Moldova, Romania and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06799520Lupus Erythematosus, Systemic · Bulgaria, Moldova, Romania and more1Active, not recruitingOct 19, 202630
NCT05418101Autoimmune Diseases · Bulgaria, Germany, Moldova and more1CompletedMar 13, 202461

How it is read

Names in the registry

  • “VIS171”, 2 entries

Codes read as this program: VIS171.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.